nav-left cat-right
cat-right

NIH awarded nine awards for NCATS’ New Therapeutic Uses

NIH awarded $12.7 million for nine awards for NCATS’ New Therapeutic Uses program which matches academic research groups with a selection of pharmaceutical industry compounds to explore new treatments for patients. Christopher Austin comments “These awards will support cooperative agreements with nine different academic research groups that are going to conduct pre-clinical validation — clinical feasibility studies and, frequently, proof-of-concept clinical trials to test whether the selected compounds may be effective against the disease that has been identified by academic researchers.

And these nine awards cover eight different disease areas, and they’re in the press release because some of these are not easily spellable. But they are Alzheimer’s disease; peripheral arterial disease; a progressive lung disease called lymphangioleiomyomatosis, or LAM, a smoking cessation; another rare disease called Duchenne muscular dystrophy; calcific aortic valve stenosis; alcoholism; and two different approaches to cognitive impairment and schizophrenia.

NCATS